Cancer Discov. 2016 Jun;6(6):OF3. doi: 10.1158/2159-8290.CD-NB2016-057. Epub 2016 May 5.
The FDA has approved cabozantinib, a tyrosine kinase inhibitor, for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. In a randomized phase III trial, participants who received cabozantinib did better across three efficacy endpoints-progression-free survival, overall survival, and objective response rate-than those given the mTOR inhibitor everolimus.
美国食品药品监督管理局已批准卡博替尼，一种酪氨酸激酶抑制剂，用于先前接受过抗血管生成治疗的晚期肾细胞癌患者。在一项随机的 III 期临床试验中，接受卡博替尼治疗的患者在三个疗效终点——无进展生存期、总生存期和客观缓解率——的表现均优于接受 mTOR 抑制剂依维莫司治疗的患者。
